Compare Stocks: BCTX, KRRO, HUMA, and RNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX Briacell Therap	$4.04 -1.7%	$3.72	$2.60 ▼ $14.68	$35.15M	1.21	146,670 shs	104,918 shs
HUMA Humacyte	$0.52 +3.7%	$0.62	$0.50 ▼ $2.55	$144.87M	2.44	3.38 million shs	5.35 million shs
KRRO Korro Bio	$9.64 -0.7%	$11.96	$5.20 ▼ $55.89	$141.96M	3.13	201,577 shs	153,051 shs
RNA Avidity Biosciences	$7.84 -3.7%	$11.45	$7.68 ▼ $16.77	$134.11M	N/A	436,688 shs	533,802 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX Briacell Therap	0.00%	-6.48%	+14.45%	+23.93%	-67.86%
HUMA Humacyte	0.00%	-6.42%	-12.50%	-26.55%	-70.37%
KRRO Korro Bio	0.00%	+0.73%	-17.04%	-31.14%	-78.04%
RNA Avidity Biosciences	0.00%	-5.43%	-46.30%	-42.56%	-81.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX Briacell Therap	$4.04 -1.7%	$3.72	$2.60 ▼ $14.68	$35.15M	1.21	146,670 shs	104,918 shs
HUMA Humacyte	$0.52 +3.7%	$0.62	$0.50 ▼ $2.55	$144.87M	2.44	3.38 million shs	5.35 million shs
KRRO Korro Bio	$9.64 -0.7%	$11.96	$5.20 ▼ $55.89	$141.96M	3.13	201,577 shs	153,051 shs
RNA Avidity Biosciences	$7.84 -3.7%	$11.45	$7.68 ▼ $16.77	$134.11M	N/A	436,688 shs	533,802 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX Briacell Therap	0.00%	-6.48%	+14.45%	+23.93%	-67.86%
HUMA Humacyte	0.00%	-6.42%	-12.50%	-26.55%	-70.37%
KRRO Korro Bio	0.00%	+0.73%	-17.04%	-31.14%	-78.04%
RNA Avidity Biosciences	0.00%	-5.43%	-46.30%	-42.56%	-81.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCTX Briacell Therap	1.00	Sell	N/A	N/A
HUMA Humacyte	2.71	Moderate Buy	$6.54	1,154.39% Upside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	73.38% Upside
RNA Avidity Biosciences	2.25	Hold	$63.75	713.14% Upside

Current Analyst Ratings Breakdown

Latest BCTX, KRRO, HUMA, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/14/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
8/13/2026	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Speculative Buy	$2.00 ➝ $1.00
8/12/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
8/6/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/3/2026	RNA Avidity Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/28/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
7/17/2026	BCTX Briacell Therap	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	HUMA Humacyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	KRRO Korro Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$9.20 per share	N/A
HUMA Humacyte	$2.04M	71.02	N/A	N/A	$0.02 per share	26.08
KRRO Korro Bio	$6.39M	22.22	N/A	N/A	$5.46 per share	1.77
RNA Avidity Biosciences	$35.84M	3.74	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCTX Briacell Therap	-$26.31M	-$7.92	N/A	N/A	N/A	N/A	-153.53%	-129.26%	N/A
HUMA Humacyte	-$40.83M	-$0.49	N/A	N/A	N/A	-4,556.29%	-983.32%	-88.84%	11/11/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	N/A	-114.26%	-68.57%	11/11/2026 (Estimated)
RNA Avidity Biosciences	N/A	-$2.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)

Latest BCTX, KRRO, HUMA, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/12/2026	Q2 2026	HUMA Humacyte	-$0.1134	-$0.16	-$0.0466	-$0.16	$1.04 million	$0.41 million
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCTX Briacell Therap	N/A	7.07	7.07
HUMA Humacyte	2.07	6.21	5.74
KRRO Korro Bio	N/A	9.55	9.55
RNA Avidity Biosciences	N/A	8.73	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCTX Briacell Therap	15.42%
HUMA Humacyte	44.71%
KRRO Korro Bio	13.18%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
BCTX Briacell Therap	0.74%
HUMA Humacyte	3.10%
KRRO Korro Bio	4.80%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCTX Briacell Therap	4	8.70 million	8.64 million	No Data
HUMA Humacyte	184	277.80 million	269.19 million	Optionable
KRRO Korro Bio	57	14.73 million	14.02 million	No Data
RNA Avidity Biosciences	190	17.11 million	16.45 million	Optionable

BCTX, KRRO, HUMA, and RNA Headlines

Recent News About These Companies

Avidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened

September 29, 2026 | marketbeat.com

Brokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) Target Price at $63.75

September 24, 2026 | americanbankingnews.com

Avidity Biosciences stock leaves Nasdaq after Novartis deal

September 23, 2026 | ad-hoc-news.deA

Avidity Biosciences stock gains 4.79 percent as RNA trades at USD 9.18

September 22, 2026 | ad-hoc-news.deA

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 21, 2026 | prnewswire.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Rating of "Hold" by Brokerages

September 19, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Share Price Passes Below Two Hundred Day Moving Average - Here's Why

September 18, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?

September 10, 2026 | marketbeat.com

Novartis RNA drug falls short in rare muscle disease study

September 9, 2026 | finance.yahoo.com

Novartis’ $12B Avidity bet suffers Phase 3 blow

September 8, 2026 | european-biotechnology.comE

Atrium Therapeutics to Participate in Upcoming Investor Conferences

September 2, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 20, 2026 | prnewswire.com

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

August 13, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

August 13, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | prnewswire.com

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

July 14, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 23, 2026 | prnewswire.com

Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth

June 14, 2026 | finance.yahoo.com

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

June 12, 2026 | biopharmadive.comB

Atrium Therapeutics Reports First Quarter 2026 Financial Results

May 14, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

April 23, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BCTX, KRRO, HUMA, and RNA Company Descriptions

Briacell Therap NASDAQ:BCTX

$4.04 -0.07 (-1.70%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.18 +0.15 (+3.59%)

As of 10/2/2026 07:30 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Humacyte NASDAQ:HUMA

$0.52 +0.02 (+3.70%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.52 -0.01 (-1.05%)

As of 10/2/2026 07:55 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Korro Bio NASDAQ:KRRO

$9.64 -0.07 (-0.72%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.67 +0.03 (+0.27%)

As of 10/2/2026 07:30 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$7.84 -0.30 (-3.69%)

As of 10/2/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCTX, KRRO, HUMA, and RNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCTX, KRRO, HUMA, and RNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCTX, KRRO, HUMA, and RNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BCTX, KRRO, HUMA, and RNA Company Descriptions

Briacell Therap NASDAQ:BCTX

Humacyte NASDAQ:HUMA

Korro Bio NASDAQ:KRRO

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCTX, KRRO, HUMA, and RNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCTX, KRRO, HUMA, and RNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCTX, KRRO, HUMA, and RNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BCTX, KRRO, HUMA, and RNA Company Descriptions

Briacell Therap NASDAQ:BCTX

Humacyte NASDAQ:HUMA

Korro Bio NASDAQ:KRRO

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools